Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb
It's been a great year for most investors, with the S&P 500 index rising close to 20% in 2017. But not every stock has performed that well. The stocks of two S&P 500 members, GlaxoSmithKline (NYSE: GSK) and Bristol-Myers Squibb (NYSE: BMY), did much worse.
The past is the past, though. What really matters is how these stocks will perform in the future. Which big pharma stock is the better choice for long-term investors? Here's how GlaxoSmithKline and Bristol-Myers Squibb compare.
Image source: Getty Images.
Source: Fool.com
Bristol-Myers Squibb Aktie
44,48 €
-0,63 %
Mehrere Buy-Einschätzungen bei Bristol-Myers Squibb, die die Sell-Zahlen überflügeln.
Eine deutliche Steigerung um mehr als 50% ist für Bristol-Myers Squibb mit einem Kursziel von 70 € gegenüber 44.48 € zu erwarten.
